Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | GPR142 | Q7Z601 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783139 | 1.00 | DPP4 (0.45) | DPP4DPP8DPP9OPRD1GPR88 | |
| SCHEMBL19699150 | 1.00 | DPP4 (0.45) | DPP4DPP8DPP9OPRD1GPR88 | |
| Hydrochloric Acid SCHEMBL1631417 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9OPRD1GPR88 | |
| Hydrochloric Acid SCHEMBL27505777 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9OPRD1GPR88 | |
| Hydrochloric Acid SCHEMBL7385109 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9OPRD1GPR88 | |
| Hydrochloric Acid SCHEMBL7276844 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9OPRD1GPR88 | |
| SCHEMBL7299950 | 0.85 | DPP4 (0.44) | DPP4DPP8DPP9OPRD1GPR88 | |
| SCHEMBL21299168 | 0.84 | DPP4 (0.45) | DPP4DPP8DPP9OPRD1GPR88 | |
| SCHEMBL3136686 | 0.84 | DPP4 (0.43) | DPP4DPP8DPP9OPRD1GPR88 | |
| SCHEMBL11922954 | 0.83 | CTSK (0.38) | DPP4DPP8DPP9GPR88CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787482-B2 | Epoxyketone compounds for enzyme inhibition | Centrax International Inc. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-10640533-B2 | Epoxyketone compounds for enzyme inhibition | CENTRAX INTERNATIONAL, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200087343-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | CENTRAX INTERNATIONAL, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| EP-3166933-B1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | CENTRAX INT INC (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017214359-A1 | NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS | VENENUM BIODESIGN LLC (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170158734-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | CENTRAX INTERNATIONAL, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170158734-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | CENTRAX INTERNATIONAL, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8088770-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088770-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7932240-B2 | Phosphadiazine HCV polymerase inhibitors IV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2009008989-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-4994477-A | Hypotensive agents | ABBOTT LABORATORIES (US) | 1991-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | SLC10A1, SLC10A2, SLC26A4 | DPP4 629/4885DPP8 769/4885DPP9 1274/4885 |
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | POLI, ITPA, POLR2H | DPP4 317/4885DPP8 921/4885DPP9 1300/4885 |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | DPP4 2985/4885DPP8 3178/4885DPP9 2725/4885 |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | DPP4 1768/4885DPP8 2990/4885DPP9 1766/4885 |
| US-10787482-B2 | Epoxyketone compounds for enzyme inhibition | PSMD10, PSMC1, PSMB10 | DPP4 1169/4885DPP8 620/4885DPP9 1037/4885 |
| US-10640533-B2 | Epoxyketone compounds for enzyme inhibition | PSMD10, PSMC1, PSMB10 | DPP4 1169/4885DPP8 620/4885DPP9 1037/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | DPP4 1509/4885DPP8 2790/4885DPP9 1550/4885 |
| US-20170158734-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | PSMD10, PSMC1, PSMB10 | DPP4 1169/4885DPP8 620/4885DPP9 1037/4885 |
| US-20200087343-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | PSMD10, PSMC1, PSMB10 | DPP4 1169/4885DPP8 620/4885DPP9 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.